The European Commission has approved Roche’s Ocrevus (ocrelizumab) for both relapsing-remitting multiple sclerosis (RRMS) and primary-progressive multiple sclerosis (PPMS) across the 28-member European Union.
The commission’s move — nearly 10 months after the U.S. Food and Drug Administration (FDA) approved Ocrevus in March 2017 — makes it the first approved PPMS treatment in Europe.
The Swiss pharmaceutical giant didn’t specify when patients can expect the treatment to become available in individual EU member states, but said it is working with authorities to provide access as quickly as possible.
“For people in Europe living with MS, today’s approval of Ocrevus by the European Commission signifies an important advance in the treatment of their disease,’’ Dr. Sandra Horning, Roche’s chief medical officer and head of Global Product Development, said in a press release. “Ocrevus is the first medicine to be approved for primary progressive MS, a debilitating form in which irreversible disability accumulates rapidly, and it